![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Boehringer Ingelheim Pharma Gmbh & Co. Kg Ingelheim Am Rhein De, based in Germany, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Adrenaline, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2009-274 - Rev 00
This Chemical Type CEP, issued on March 17, 2016, remains in force until February 04, 2021, ensuring its reliability within the pharmaceutical industry.
Substance Number 2303 associated with this CEP further emphasizes